Dr. Lal PathLabs Q2 FY25 consolidated net profit up at Rs. 129.2 Cr

Dr. Lal Path Labs has reported total income of Rs. 682.1 crores during the period ended September 30, 2024

Thyrocare Technologies posts Q2 FY25 consolidated net profit at of Rs. 26.67 Cr

Thyrocare Technologies has reported total income of Rs. 179.97 crores during the period ended September 30, 2024

Jagsonpal Pharmaceuticals Q2 FY25 net profit up at Rs. 11.45 Cr

Jagsonpal Pharmaceuticals has reported total income of Rs. 76.34 crores during the period ended September 30, 2024

Syngene International posts Q2 FY25 consolidated PAT at Rs. 106.1 Cr

Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr

Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024

Solara Active Pharma Sciences reports consolidated Q2 FY25 net profit at Rs. 8.01 Cr

Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024

JB Pharma outlines key ESG goals & targets in Third Sustainability Report FY24

JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%

Piramal Pharma releases Sustainability Report FY 2023-24

The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence

Chemify gets grant to design and discover new drug leads for Tuberculosis and Malaria

Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules

FDA approves Bristol Myers Squibb’s Cobenfy

A first-in-class muscarinic agonist for the treatment of schizophrenia in adults